Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

被引:773
作者
Deng, Lisi [1 ]
Li, Chunna [1 ]
Zeng, Qi [2 ]
Liu, Xi [1 ]
Li, Xinghua [1 ]
Zhang, Haitang [1 ]
Hong, Zhongsi [1 ]
Xia, Jinyu [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, 52 East Meihua Rd, Zhuhai 519000, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 5, Canc Ctr, Zhuhai, Guangdong, Peoples R China
关键词
Corona Virus Disease 2019; Arbidol; Lopinavir/ritonavir; Antiviral intervention; Combination therapy; ACUTE RESPIRATORY SYNDROME; LOPINAVIR/RITONAVIR; SARS; MANAGEMENT;
D O I
10.1016/j.jinf.2020.03.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only. Methods: In this retrospective cohort study, we included adults (age >= 18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7). Results: We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 005). After 14 days, 15 (94%) of 16 and 9 (52 9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0 05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0 05). Conclusion: In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E1 / E5
页数:5
相关论文
共 25 条
[1]  
[Anonymous], CLIN MAN SEV AC RESP
[2]   Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome [J].
Arabi, Yaseen M. ;
Mandourah, Yasser ;
Al-Hameed, Fahad ;
Sindi, Anees A. ;
Almekhlafi, Ghaleb A. ;
Hussein, Mohamed A. ;
Jose, Jesna ;
Pinto, Ruxandra ;
Al-Omari, Awad ;
Kharaba, Ayman ;
Almotairi, Abdullah ;
Al Khatib, Kasim ;
Alraddadi, Basem ;
Shalhoub, Sarah ;
Abdulmomen, Ahmed ;
Qushmaq, Ismael ;
Mady, Ahmed ;
Solaiman, Othman ;
Al-Aithan, Abdulsalam M. ;
Al-Raddadi, Rajaa ;
Ragab, Ahmed ;
Balkhy, Hanan H. ;
Al Harthy, Abdulrahman ;
Deeb, Ahmad M. ;
Al Mutairi, Hanan ;
Al-Dawood, Abdulaziz ;
Merson, Laura ;
Hayden, Frederick G. ;
Fowler, Robert A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (06) :757-767
[3]   Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy [J].
Barnard, Dale L. ;
Kumaki, Yohichi .
FUTURE VIROLOGY, 2011, 6 (05) :615-631
[4]   Arbidol as a broad-spectrum antiviral: An update [J].
Blaising, Julie ;
Polyak, Stephen J. ;
Pecheur, Eve-Isabelle .
ANTIVIRAL RESEARCH, 2014, 107 :84-94
[5]   Arbidol:: A broad-spectrum antiviral compound that blocks viral fusion [J].
Boriskin, Y. S. ;
Leneva, I. A. ;
Pecheur, E. -I. ;
Polyak, S. J. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (10) :997-1005
[6]   A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster [J].
Chan, Jasper Fuk-Woo ;
Yuan, Shuofeng ;
Kok, Kin-Hang ;
To, Kelvin Kai-Wang ;
Chu, Hin ;
Yang, Jin ;
Xing, Fanfan ;
Liu, Jieling ;
Yip, Cyril Chik-Yan ;
Poon, Rosana Wing-Shan ;
Tsoi, Hoi-Wah ;
Lo, Simon Kam-Fai ;
Chan, Kwok-Hung ;
Poon, Vincent Kwok-Man ;
Chan, Wan-Mui ;
Ip, Jonathan Daniel ;
Cai, Jian-Piao ;
Cheng, Vincent Chi-Chung ;
Chen, Honglin ;
Hui, Christopher Kim-Ming ;
Yuen, Kwok-Yung .
LANCET, 2020, 395 (10223) :514-523
[7]   Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [J].
Chu, CM ;
Cheng, VCC ;
Hung, IFN ;
Wong, MML ;
Chan, KH ;
Chan, KS ;
Kao, RYT ;
Poon, LLM ;
Wong, CLP ;
Guan, Y ;
Peiris, JSM ;
Yuen, KY .
THORAX, 2004, 59 (03) :252-256
[8]  
Chung M, 2020, RADIOLOGY
[9]   Lopinavir/ritonavir - A review of its use in the management of HIV infection [J].
Cvetkovic, RS ;
Goa, KL .
DRUGS, 2003, 63 (08) :769-802
[10]  
Dong Xuan, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, https://doi.org/10.1016/S0140-6736(20)30183-5, DOI 10.1016/S0140-6736(20)30211-7]